Related Experiment Video
Updated: Jun 10, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
Regression of left ventricular hypertrophy in hemodialyzed patients is possible: a follow-up study
Şerban Ardeleanu1, Larisa Panaghiu, Octavian Prisadă
1Dialysis and Transplantation Center, Dr CI Parhon University Hospital, Blvd Carol 1st No 50, 700503 Iaşi, Romania. serbard@yahoo.com
Insights
Regression of left ventricular hypertrophy (LVH) is achievable in hemodialyzed patients. Serial echocardiography showed significant LVH regression and improved cardiac structure over a 10-year period, highlighting a key objective for dialysis centers.
Area of Science:
- Cardiology
- Nephrology
- Medical Imaging
Background:
- Limited research exists on serial changes in left ventricular mass (LVM) and associated risk factors.
- Echocardiographic assessment of left ventricular (LV) structure and function trends over a decade in hemodialysis patients was investigated.
Purpose of the Study:
- To describe trends in LV structure and function using echocardiography over 10 years.
- To compare current findings with previous data from a smaller patient cohort.
- To identify factors influencing changes in LV mass index (LVMi) in hemodialysis patients.
Main Methods:
- A cohort of 334 hemodialyzed patients was followed from January 1999 to March 2009.
- Serial echocardiography was performed throughout the study period.
- Mean biochemical parameters (hemoglobin, serum proteins, calcium, phosphate) were analyzed alongside echocardiographic data.
Main Results:
- A 70.5% survival rate was observed at the study's end.
- Significant regression of left ventricular hypertrophy (LVH) was noted, with LVMi decreasing by 15.4% in patients with complete data.
- Relative wall thickness also showed significant regression (0.46 to 0.42).
- Changes in LVMi correlated significantly with hemoglobin level fluctuations.
Conclusions:
- Regression of LVH is attainable in hemodialysis patients.
- Achieving LVH regression is a critical goal for dialysis centers.
- Serial echocardiography is valuable for monitoring cardiac remodeling in this population.
Background:
Few studies have addressed the description of serial changes in left ventricular mass (LVM) and relevant risk factors. The aims of our study were to describe trends in left ventricular (LV) structure and function derived from echocardiographic measurements over a 10-year period in Fresenius Nephrocare Dialysis Center in Iaşi and to compare the results with those obtained on a smaller group 4 years ago.
Methods:
Three hundred and thirty-four hemodialyzed patients were enrolled at baseline, between January 1999 and March 2009. Echocardiography was performed at inclusion and several times for each patient during this period, until the end of the study. Mean values of the biochemical parameters (hemoglobin, serum proteins, calcium, phosphate) at the time of the echocardiographic examination were calculated and included in the final analysis.
Results:
Outcome in dialysis was 70.5% alive at the end of the study. The most important improvement was observed in LV mass index: at the 4th echocardiography, the mean LVMi was 144.8 vs. 156.0 g/m(2) at the 2nd echocardiographic examination vs. 167.2 g/m(2) at the first echocardiographic examination (mean decrease 3.34 ± 9.6 g/m(2)/month). Significant results were obtained by comparing LVMi only in patients with all 4 echocardiographies: left ventricular hypertrophy regression was statistically significant, from 172.7 g/m(2) at the 1st echocardiography to 146.0 g/m(2) at the 4th, i.e. 15.4% reduction of LVMi. Delta LVMi significantly correlated only with changes in hemoglobin (P < 0.05).There was a significant regression of the relative wall thickness from an average of 0.46 to 0.42 (P < 0.05).
Conclusion:
Our study proves that regression of LVH in hemodialyzed patients is possible and constitutes a must-achieve objective in dialysis centers.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure V: Medical Management
Mitral Regurgitation IV: Nursing Management
Mitral Regurgitation I: Introduction
